MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX) today announced its financial results according to International Financial Reporting Standards (IFRS) for the three-months’ period and fiscal year ending December 31, 2004. Operational Highlights of the Year 2004:
- Conclusion of a major therapeutic antibody collaboration with Novartis AG
 - Expansion of the Company’s research antibody business unit, “Antibodies by Design”, which was further strengthened through the acquisition of the Biogenesis Group in the U.K. and U.S.A. in January 2005
 - Regulatory approval for first HuCAL®-derived antibody to enter human clinical trials: Commencement of Phase 1 in January 2005
 - Presentation of promising animal data from pre-clinical studies for MOR202, MorphoSys´ latest proprietary antibody therapeutic focused on the treatment of multiple myeloma
 - Conclusion of a collaboration with Novoplant GmbH for wholly new applications of MorphoSys antibodies in veterinary medicine - Signing of a marketing agreement with GeneFrontier Corp. to access the Japanese life science market for antibody research reagents and antibody therapeutics
 - Commencement of a new therapeutic antibody program with Boehringer Ingelheim in cardiovascular diseases - Early extension of existing agreement with Centocor (Johnson & Johnson) to the end of 2007
 - Extension of existing collaboration with Schering AG until up to 2007
 - Granting of U.S. Patent for proprietary CysDisplayTM screening technology Financial Highlights of the Year 2004:
 - Attainment of first full year of profitability
- Improvement of revenues by 44% over prior year
 - Cash position increase of over 60% compared to prior year
 - Novartis purchased an equity stake of approximately 10% in MorphoSys
 - Inclusion in the Frankfurt Stock Exchange TecDAX Index
- MorphoSys awarded for Corporate Governance Excellence

Please click here to read up on the details of this press release (PDF-file).